H.C. Wainwright initiated coverage of Larimar Therapeutics with a Buy rating and $15 price target The firm says Larimar’s nomlabofusp could be the first therapy to address the root cause of Friedreich’s ataxia. The Phase 2 data showed nomlabofusp was generally well tolerated and demonstrated dose dependent increases in frataxin levels in skin and buccal cells, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics initiated with a Buy at JonesResearch
- Larimar Therapeutics initiated with an Outperform at Baird
- Larimar Therapeutics sees cash runway into 2026
- Larimar Therapeutics plans PK run-in study in adolescents, children with FA
- Larimar Therapeutics reports Q2 EPS (34c), consensus (30c)